CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Werner R, Haug A, Buske C, Heidegger S, et al. Nuklearmedizin 2024;63:57-61.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Werner R, Haug A, Buske C, Heidegger S, et al. CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. Nuklearmedizin 2024;63:57-61.
PMID: 38190998